Drug Trial Radar · NCT00516477
Safety Study in Subjects With Leber Congenital Amaurosis
Last checked: Nov 20, 2026Latest source record: Nov 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Planned (sponsor's estimate)
Start
Sep 2007
Primary completion
Mar 20, 2018
Study completion Mar 20, 2018
Sponsor
- Lead sponsor
- Spark Therapeutics, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Aug 15, 2007
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether gene transfer will be safe and effective in the treatment of Leber Congenital Amaurosis (LCA).
Conditions
- Leber Congenital Amaurosis
Interventions
voretigene neparvovec-rzylBiological
Subjects will be dosed unilaterally (one eye) beginning with the lowest dose. Subjects will be injected with AAV2-hRPE65v2 by means of a subretinal injection. Dose escalation to the next cohort will be dependent on assessment of the safety data by the DSMB out to at least 4 weeks following the injection. Because there is a delay between time of delivery of AAV2 and the peak transgene expression there will be a delay of six weeks between all subjects.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary outcome measures are safety and tolerability. Secondary outcome measure(s) include changes in visual function as measured by subjective, psychophysical tests and by objective, physiologic tests.Time frame: Visual function will be measured at designated intervals from baseline visits through 5 years as stated in the protocol.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.